Sun Pharma Stock Price Up Today After Company Launches LEQSELVI in US
By Ankur Chandra | Published at: Jul 15, 2025 02:48 PM IST
Mumbai, July 15, 2025 – Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA, BSE: 524715) announced the launch of LEQSELVI™ (deuruxolitinib) in the United States for the treatment of severe alopecia areata. Following the announcement, the company’s stock price gained. At 2:36 p.m. 15th July, 2025, its stock price was up by 2.65% at Rs 1,727.20.
Key Trading Metrics (as of 1:30 PM IST)
| Metric | Value |
|---|---|
| Last Traded Price | ₹1,725 |
| % Change | +2.54% |
| VWAP | ₹1,708.21 |
| Day’s High / Low | ₹1,728.00 / ₹1,687.90 |
| Buy Quantity | 1,68,465 |
| Sell Quantity | 2,03,129 |
| Traded Volume (in Lakhs) | 22.17 |
| Traded Value (in ₹ Crore) | 378.65 |
| Total Market Cap (in ₹ Crore) | 4,13,597.36 |
| Free Float Market Cap (₹ Cr.) | 1,85,473.18 |
LEQSELVI™ Launch Fuels Investor Optimism
The rally comes a day after Sun Pharma disclosed its US launch of LEQSELVI™, an oral JAK1/JAK2 inhibitor indicated for treating severe alopecia areata. The drug demonstrated rapid efficacy during clinical trials, with one-third of patients regaining nearly full scalp hair by Week 24. Some patients showed significant results as early as 8 weeks.
“Adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community,” said Richard Ascroft, CEO, Sun Pharma North America.
The company is also offering LEQSELVI SUPPORT™, a program that may reduce patient costs to as low as $0 for up to two years.
Regulatory Note and Safety Info
The launch aligns with Sun Pharma’s strategic focus on expanding its specialty product pipeline globally. However, LEQSELVI comes with a boxed warning and potential side effects, including the risk of serious infections, thrombosis, and cardiovascular events. It is not recommended for patients with CYP2C9 poor metabolism or those using CYP2C9 inhibitors.
Sun Pharmaceutical Industries Stock Performance
As of 1:26 PM IST, Sun Pharmaceutical Industries shares are trading at ₹1,725, representing a 2.54% increase from July 15, 2025. Sun Pharmaceutical Industries shares have gained 8.78% in the last year, down 8.7% year-to-date, and up 2.7% in the previous month.
About Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd is India’s largest pharma company and a leading generic manufacturer in the U.S., with a presence in over 100 countries. The company is part of the NIFTY 50 index and has been listed on Indian exchanges since February 1995. Its business spans specialty, generics, and consumer healthcare, with dermatology being a key area of focus.
REF: https://nsearchives.nseindia.com/corporate/SUNSEC_14072025164719_SEIntimationforLaunch.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
